What is ROIV's health score?

Roivant Sciences Ltd. (ROIV) has a TradeApes health score of 40 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ROIV's estimated fair value?

Based on our 5-year discounted cash flow model, Roivant Sciences Ltd.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is ROIV undervalued or overvalued?

Our model currently rates ROIV as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for ROIV... Refresh in a moment for the full analysis.

Roivant Sciences Ltd. (ROIV)

Healthcare Inconclusive inconclusive weak

$28.58

Updated: 2026-06-06

TradeApes Score

Financial Strength

40 Weak

Operating Trend

20 Stressed

Relative Value

40 Weak

Capital Allocation

45 Mixed

Risk

80 Strong

Key Findings

+ Active buybacks — share count declining, capital returned to owners

Unlock Full Report →

− Sharp revenue decline — sales down more than 15% year over year

Unlock Full Report →

Create an account for unlimited access

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.